Compound ID | 1782
Program 1
Class: Aminoglycoside
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Enterobacteriaceae and Pseudomonas aeruginosa |
| Description: | Semisynthetic compound |
| Institute where first reported: | Revagenix |
| Year first mentioned: | 2019 |
| Highest developmental phase: | Preclinical |
| Development status: | Active (as of 2022) |
| External links: | |
| Citation: | https://www.revagenix.com/company |
| Patent: | GB2584009B |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.